We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Valirx Plc | LSE:VAL | London | Ordinary Share | GB00BLH13C52 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.15 | -4.35% | 3.30 | 3.20 | 3.40 | 3.45 | 3.30 | 3.45 | 97,650 | 09:14:30 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 0 | -2.37M | -0.0262 | -1.26 | 2.98M |
TIDMVAL
RNS Number : 0054B
ValiRx PLC
02 October 2020
VALIRX PLC
("ValiRx", the "Company" or the "Group")
Exercise of Warrant
London, UK 2 October 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company announces it has received notification for the exercise of warrants over 40,000 ordinary shares in the Company at an exercise price of 12.5 pence per share providing the Company with proceeds of GBP5,000 ("Warrant Exercise").
Application will be made to the London Stock Exchange to admit the 40,000 new ordinary shares resulting from the Warrant Exercise to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 8 October 2020. The new ordinary shares will rank pari passu with the existing ordinary shares.
For the purposes of the Disclosure and Transparency Rules, following the issue of shares detailed above as a result of the Warrant Exercise, the enlarged issued share capital of the Company will comprise 64,028,325 ordinary shares of 0.1 pence each. The Company does not hold any shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information please contact:
ValiRx plc Tel: +44 (0) 20 7073 2628 www.valirx.com Suzanne Dilly Suzanne.Dilly@valirx.com Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213 Adviser) 0880 Liam Murray / Jo Turner / Ludovico Lazzaretti Peterhouse Capital Limited (Sole Broker) Tel: +44 (0) 20 7469 Duncan Vasey / Lucy Williams / Eran Zucker 0930 Optimum Strategic Communications Tel: +44 (0) 20 8148 Supriya Mathur/ Shabnam Bashir 3040 valirx@optimumcomms.com About ValiRx ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework to enable rapid translation of innovative science into clinical development. With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets. Integrating science and business We connect diverse disciplines across scientific, technical and commercial domains, with the promise of achieving a more streamlined, less costly, drug development process. We work closely with our selected collaborators and leverage the combined expertise required for science to advance. Lead candidates from our portfolio are out-licenced or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. https://www.valirx.com/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
IOEEALEAELSEFFA
(END) Dow Jones Newswires
October 02, 2020 11:00 ET (15:00 GMT)
1 Year Valirx Chart |
1 Month Valirx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions